NCT06778395View on ClinicalTrials.gov

Therapeutic Effect of Vonoprazan Versus Dexlansoprazole in Treatment of Gastroesophageal Reflux Disease

PHASE4CompletedINTERVENTIONAL
Enrollment

136

Participants

Timeline

Start Date

October 1, 2024

Primary Completion Date

December 31, 2024

Study Completion Date

December 31, 2024

Conditions
VonoprazanProton Pump InhibitorGastroesophageal Reflux Disease
Interventions
DRUG

Dexlansoprazole 60 mg

once daily for 8 weeks

DRUG

Vonoprazan 20 mg bid

twice daily for 8 weeks

Trial Locations (1)

44519

Zagazig University Hospital, Zagazig

All Listed Sponsors
collaborator

Zagazig University

OTHER_GOV

lead

Ayman Magd Eldin Mohammad Sadek

OTHER_GOV

NCT06778395 - Therapeutic Effect of Vonoprazan Versus Dexlansoprazole in Treatment of Gastroesophageal Reflux Disease | Biotech Hunter | Biotech Hunter